Lowering High Blood Pressure Can Reverse Some Dementia in the Elderly
WebMD News Archive
May 18, 2001 (San Francisco) -- Three years ago Charles Vincent
was overweight and had high blood pressure and high cholesterol. Worse, he was
having trouble with his memory, having one too many "Alzheimer's
Today, his blood pressure is a healthy 130/75, he is 20 pounds
lighter, and his cholesterol is fine, even by the new stricter standards issued
this week. Most of all, "I may not be as sharp as I was when I was 20, but
I can do math faster than most 20-year-olds."
And just two days ago Vincent celebrated his 83rd birthday.
The difference between 1999 and this year can be explained by
his blood pressure, says Edwin Jacobson, MD. Jacobson says that about 40% of
dementia symptoms are caused not by Alzheimer's disease but by high blood
pressure, a condition called vascular dementia.
Jacobson, a clinical professor of medicine at UCLA school of
medicine, says that in a study of 66 patients with high blood pressure as well
as mild dementia symptoms, controlling blood pressure meant that
"progression of dementia was stopped and some effects of cognitive
impairment were reversed." He presented his findings here this week at the
16th Scientific Meeting of the American Society of Hypertension.
Vincent, a retired business executive, tells WebMD that just a
year ago his blood pressure was 160/90, not considered dangerously high
"but high enough to affect my memory and ability to think clearly."
Jacobson says that a magnetic resonance scan of Vincent's brain
confirmed that Vincent's brain had many small white scars, the type of damage
that is associated with tiny, silent strokes. These silent strokes are
"markers for vascular dementia," says Jacobson.
Jacobson says that many researchers have described the link
between high blood pressure and dementia, but no one has attempted to reverse
the dementia by controlling blood pressure.
In his study, 24 women and 42 men, aged 65 to 80, with high
blood pressure and vascular dementia (as confirmed by magnetic resonance
scans), were randomly chosen to take one of two different types of blood
pressure medications. One drug, Vasotec, is what's called an ACE inhibitor, and
the other drug, Plendil, is what's known as a calcium channel blocker.
AstraZeneca, maker of Plendil, funded the study.
In addition to magnetic resonance scans, the patients were also
assessed using memory and psychological tests. At study onset the scores on
those tests were about "20% to 40% below normal. That means that these were
people who were functioning but they were becoming limited. For example, they
didn't wander off, but you wouldn't want these patients driving," says
Jacobson says that drug doses were increased until the patient
reached the blood pressure goal of 130/90. Using this aggressive treatment
approach "patients reached the goal by 12 weeks," says Jacobson. All
patients had repeat memory and psychological tests at 12 weeks and again at six